Why did Biohaven skyrocket 70% after Pfizers deal?
理财鱼小提示：Why did Biohaven skyrocket 70% after Pfizer's deal?
Migraine pill maker Biohaven Pharmaceutical surged 68% on Tuesday to $140 after drugmaker Pfizer announced to spend $11.6 billion for the acquisition of the company.
Pfizers will pay $148.5 per share in cash, a 33% premium over Biohaven's three-month average stock price, and an even larger 78.6% premium to its closing price on Monday.
With its fame based on the flagship product Nurtec ODT, the first oral pill approved for both acute migraine treatment and prevention, Biohaven is basically the superstar of the migraine market.
However, that's not the only reason why it deserved a 70% gain.
According to Bloomberg, biotech stocks have been way too cheap for quite some time, nearly 200 biotech companies have their reserves worth more than their market value.
As a result, investors have long been waiting for deals to revive the sector, and Pfizer taking the first big step becomes a singal that "perhaps it also will be a harbinger of more biotech dealmaking ahead."
>相关《 Why did Biohaven skyrocket 70% after Pfizers deal?》内容：
1、 被辉瑞买下后暴涨 70%！Biohaven 凭什么？
理财鱼小提示：被辉瑞买下后暴涨 70%！Biohaven 凭什么？ 隔夜美股继续震荡，最后关头才靠科技股的反弹救了一把。 然而，有一家公司却从盘前就保持稳稳的涨势，涨幅甚至达到惊人的 70%——那就是刚刚被全球生物制药巨头辉瑞（Pfizer）斥资百亿美元买下的创新生物...【继续阅读】
2、 Adyen携手Afterpay扩大全球合作
Afterpay（在英国和欧洲称为"Clearpay"）将利用Adyen在各主要市场的本地零售 悉尼2022年5月10日 /美通社/ -- 服务于领先企业的全球金融技术平台Adyen（AMS：ADYEN）今天宣布扩大与先买后付（BNPL）领域的领先企业Afterpay Limited（ASX: APT）的合作。Afte...【继续阅读】
3、 Biohaven(BHVN.US)盘前暴涨70%！获辉瑞(PFE.US)收购
智通财经APP获悉，辉瑞(PFE.US)宣布与生物制药公司Biohaven Pharmaceutical(BHVN.US)达成协议，辉瑞将以116亿美元的现金收购Biohaven。受此消息提振，截至发稿，Biohaven周二美股盘前暴涨超71%，辉瑞则跌逾1%。 根据协议，辉瑞将以每股148.50美元现金的价...【继续阅读】